Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Jiankangyuan's Q3 2021 profits increased, with increased investment in R&D to expand growth potential.
Published Time：
2021-10-27
Currently, Joincare's layout covers chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, health products, diagnostic reagents and equipment and other multiple fields, gradually developing into an innovative R&D-oriented comprehensive pharmaceutical group with high-barrier preparation and innovative drug platform technologies, integrating R&D, production, sales, and services, with a complete industrial chain and a rich product matrix.
Data from the first three quarters shows that Joincare's chemical preparations achieved revenue of 6.907 billion yuan, a year-on-year increase of 40.96%, of which respiratory preparations achieved revenue of 274 million yuan, a year-on-year increase of 957.88%; digestive tract products achieved revenue of 2.993 billion yuan, a year-on-year increase of 68.66%; gonadotropin products achieved revenue of 1.978 billion yuan, a year-on-year increase of 37.75%; mental products achieved revenue of 306 million yuan, a year-on-year increase of 49.77%; and anti-infective products achieved revenue of 1.053 billion yuan, a year-on-year decrease of 0.19%. Raw materials and intermediates achieved revenue of 3.441 billion yuan, a year-on-year increase of 17.51%. Traditional Chinese medicine preparations achieved revenue of 853 million yuan, a year-on-year decrease of 10.53%. Diagnostic reagents and equipment achieved revenue of 552 million yuan, a year-on-year decrease of 52.64%. High technical barriers, high costs, long cycles, and high risks are important reasons for the "bottleneck" development challenges faced by respiratory drugs in China. Years of dedicated R&D, transforming scientific research strength into productive results, is one of Joincare's important strategies for transformation and growth.
In recent years, while maintaining steady development in various business segments, Joincare has focused on building four high-barrier complex preparation platforms: respiratory preparation R&D, nano-preparation R&D, lipid microemulsion preparation R&D, and transdermal preparation R&D. Guosheng Securities' report points out that the respiratory field is a key R&D area for Joincare, with a continuously advancing pipeline and many future highlights. In the future, respiratory preparation products will continue to contribute stable incremental growth to the company's performance.
Currently, Joincare's existing and under-research products have achieved coverage of all categories of asthma and COPD inhalation therapy drugs. At the same time, three major inhalation preparation products have been successfully selected for the fifth batch of national centralized procurement, which will help the company quickly open up the domestic sales market and enhance market competitiveness. From January to September 2021, Joincare's R&D investment was 959 million yuan, a year-on-year increase of 37.85%. The report shows that the increase in R&D investment is mainly due to the company's vigorous promotion of the innovative drug "recombinant novel coronavirus fusion protein vaccine" project and the expansion of the scientific research team.
In the face of the current recurring COVID-19 epidemic, the innovative recombinant novel coronavirus fusion protein vaccine (V-01) jointly developed by Lizhu Bio, a subsidiary of Joincare, and the Institute of Biophysics, Chinese Academy of Sciences, has attracted much attention. V-01 has shown four characteristics in the results of Phase I and II clinical trials: high antibody titer, balanced cellular immunity, long duration, and good safety, with impressive data. Currently, the V-01 vaccine has entered the global Phase III clinical trial stage. On August 25, the first subject was successfully enrolled in the Philippines, and applications for Phase III clinical trials have been submitted to more than 10 countries worldwide. In the future, the V-01 vaccine may become a major incremental contributor to the company's performance.
Joincare's business layout and R&D are characterized by high-barrier complex preparations, continuously enriching its product line and continuously improving its profitability. In addition, Joincare has continuously improved its corporate governance structure and optimized its equity structure through various incentive measures, which is conducive to driving the core management team to inject vitality and creativity into the company from the inside out, benefiting the company's steady performance improvement and long-term sustainable development.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.